What is the current valuation of the Psilocybin Assisted Therapy Market?

As of 2024, the Psilocybin Assisted Therapy Market was valued at 2.372 USD Billion. Read More

What is the projected market size for the Psilocybin Assisted Therapy Market by 2035?

The market is projected to reach 11.57 USD Billion by 2035. Read More

What is the expected CAGR for the Psilocybin Assisted Therapy Market during the forecast period?

The expected CAGR for the Psilocybin Assisted Therapy Market from 2025 to 2035 is 15.49%. Read More

Which applications are driving growth in the Psilocybin Assisted Therapy Market?

Key applications include Depression, Anxiety, and Post-Traumatic Stress Disorder, with Depression alone valued at 3.5 USD Billion by 2035. Read More

What are the leading formulations in the Psilocybin Assisted Therapy Market?

Tablets are anticipated to dominate the market, projected to reach 4.0 USD Billion by 2035. Read More

How does the therapeutic setting impact the Psilocybin Assisted Therapy Market?

Inpatient and outpatient settings are expected to each reach 3.5 USD Billion by 2035, indicating robust demand. Read More

What demographic segments are most relevant in the Psilocybin Assisted Therapy Market?

Adults are projected to account for 4.65 USD Billion by 2035, highlighting their significance in the market. Read More

Who are the key players in the Psilocybin Assisted Therapy Market?

Prominent players include Compass Pathways, MindMed, and Atai Life Sciences, among others. Read More

What is the market outlook for adolescents in the Psilocybin Assisted Therapy Market?

The adolescent segment is projected to reach 2.25 USD Billion by 2035, indicating a growing focus on this demographic. Read More

How does the Psilocybin Assisted Therapy Market compare across different formulations?

By 2035, tablets, capsules, and liquids are expected to collectively dominate, with tablets leading at 4.0 USD Billion. Read More

Psilocybin Assisted Therapy Market

ID: MRFR/Pharma/36883-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Psilocybin Assisted Therapy Market Research Report By Application (Depression, Anxiety, Post-Traumatic Stress Disorder, Substance Abuse, Obsessive-Compulsive Disorder), By Formulation (Liquid, Tablet, Capsule, Powder, Injection), By Therapeutic Setting (Inpatient, Outpatient, Residential Treatment, Community-Based Programs), By Patient Demographics (Adults, Adolescents, Elderly, Veterans) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Psilocybin Assisted Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)15.49%

2024 Market Size$ 2.37 Billion

2025 Market Size$ 2.74 Billion

2035 Market Size$ 11.57 Billion

Key Players

Compass Pathways

MindMed

Field Trip Health

Atai Life Sciences

Silo Wellness

Numinus Wellness

Trends

Increased Research and Development
Regulatory Changes and Acceptance
Integration of Technology in Therapy

Opportunities

Evolving Regulatory Landscape
Growing Mental Health Awareness
Growing Acceptance of Alternative Therapies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Depression
  2. 4.1.2 Anxiety
  3. 4.1.3 Post-Traumatic Stress Disorder
  4. 4.1.4 Substance Abuse
  5. 4.1.5 Obsessive-Compulsive Disorder
2. 4.2 Healthcare, BY Formulation (USD Billion)
  1. 4.2.1 Liquid
  2. 4.2.2 Tablet
  3. 4.2.3 Capsule
  4. 4.2.4 Powder
  5. 4.2.5 Injection
3. 4.3 Healthcare, BY Therapeutic Setting (USD Billion)
  1. 4.3.1 Inpatient
  2. 4.3.2 Outpatient
  3. 4.3.3 Residential Treatment
  4. 4.3.4 Community-Based Programs
4. 4.4 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.4.1 Adults
  2. 4.4.2 Adolescents
  3. 4.4.3 Elderly
  4. 4.4.4 Veterans
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Compass Pathways (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 MindMed (CA)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Field Trip Health (CA)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Atai Life Sciences (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Silo Wellness (CA)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Numinus Wellness (CA)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Havn Life Sciences (CA)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Cybin (CA)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY FORMULATION
5. 6.5 US MARKET ANALYSIS BY THERAPEUTIC SETTING
6. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY FORMULATION
9. 6.9 CANADA MARKET ANALYSIS BY THERAPEUTIC SETTING
10. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
13. 6.13 GERMANY MARKET ANALYSIS BY FORMULATION
14. 6.14 GERMANY MARKET ANALYSIS BY THERAPEUTIC SETTING
15. 6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
16. 6.16 UK MARKET ANALYSIS BY APPLICATION
17. 6.17 UK MARKET ANALYSIS BY FORMULATION
18. 6.18 UK MARKET ANALYSIS BY THERAPEUTIC SETTING
19. 6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
21. 6.21 FRANCE MARKET ANALYSIS BY FORMULATION
22. 6.22 FRANCE MARKET ANALYSIS BY THERAPEUTIC SETTING
23. 6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY FORMULATION
26. 6.26 RUSSIA MARKET ANALYSIS BY THERAPEUTIC SETTING
27. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
29. 6.29 ITALY MARKET ANALYSIS BY FORMULATION
30. 6.30 ITALY MARKET ANALYSIS BY THERAPEUTIC SETTING
31. 6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
33. 6.33 SPAIN MARKET ANALYSIS BY FORMULATION
34. 6.34 SPAIN MARKET ANALYSIS BY THERAPEUTIC SETTING
35. 6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY FORMULATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC SETTING
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
42. 6.42 CHINA MARKET ANALYSIS BY FORMULATION
43. 6.43 CHINA MARKET ANALYSIS BY THERAPEUTIC SETTING
44. 6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
46. 6.46 INDIA MARKET ANALYSIS BY FORMULATION
47. 6.47 INDIA MARKET ANALYSIS BY THERAPEUTIC SETTING
48. 6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
50. 6.50 JAPAN MARKET ANALYSIS BY FORMULATION
51. 6.51 JAPAN MARKET ANALYSIS BY THERAPEUTIC SETTING
52. 6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY FORMULATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC SETTING
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY FORMULATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC SETTING
60. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
62. 6.62 THAILAND MARKET ANALYSIS BY FORMULATION
63. 6.63 THAILAND MARKET ANALYSIS BY THERAPEUTIC SETTING
64. 6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY FORMULATION
67. 6.67 INDONESIA MARKET ANALYSIS BY THERAPEUTIC SETTING
68. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY FORMULATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC SETTING
72. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY FORMULATION
76. 6.76 BRAZIL MARKET ANALYSIS BY THERAPEUTIC SETTING
77. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
79. 6.79 MEXICO MARKET ANALYSIS BY FORMULATION
80. 6.80 MEXICO MARKET ANALYSIS BY THERAPEUTIC SETTING
81. 6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY FORMULATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC SETTING
85. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC SETTING
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC SETTING
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC SETTING
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY FORMULATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC SETTING
102. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY THERAPEUTIC SETTING, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY THERAPEUTIC SETTING, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY FORMULATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY THERAPEUTIC SETTING, 2025-2035 (USD Billion)
  4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Psilocybin Assisted Therapy Market Segmentation

Psilocybin Assisted Therapy Market By Application (USD Billion, 2025-2035)

Depression
Anxiety
Post-Traumatic Stress Disorder
Substance Abuse
Obsessive-Compulsive Disorder

Psilocybin Assisted Therapy Market By Formulation (USD Billion, 2025-2035)

Liquid
Tablet
Capsule
Powder
Injection

Psilocybin Assisted Therapy Market By Therapeutic Setting (USD Billion, 2025-2035)

Inpatient
Outpatient
Residential Treatment
Community-Based Programs

Psilocybin Assisted Therapy Market By Patient Demographics (USD Billion, 2025-2035)

Adults
Adolescents
Elderly
Veterans

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”